Multiple Sclerosis: It's Not Just About Age, But How Your Body Ages

Multiple sclerosis (MS) is a complex immune-mediated disease where the body's immune system mistakenly attacks the central nervous system, leading to a range of neurological problems. While we know aging plays a role in MS progression, a recent study in *eBioMedicine* sheds light on how different factors like sex, CMV status (a common viral infection), and specific treatments can impact the aging process of the immune system in people with MS (PwMS). This study emphasizes the need to consider these factors when studying immune markers in MS to improve prognosis and treatment strategies.

Understanding Immunosenescence in MS
As we age, our immune system undergoes changes, a process called immunosenescence. This involves a decline in immune function, chronic low-grade inflammation, and increased susceptibility to infections. This study highlights that immunosenescence may be accelerated by chronic diseases like MS. The study's authors analyzed 771 serum samples from 147 healthy controls (HC) and 289 PwMS to understand how MS and disease-modifying therapies (DMTs) affect age-sensitive immune biomarkers.

Key Findings: A Personalized Approach to MS
* MS Immune Profile: The study revealed that PwMS have a distinct immune profile characterized by lower levels of anti-inflammatory factors such as IL-4, IL-10, TNF and β-NGF, but higher levels of growth factors like EGF and bFGF.

* Influence of Sex and CMV Status: The levels of certain immune markers (IL-4, β-NGF, IL-27, BDNF, and leptin) were significantly influenced by sex and/or CMV status. This highlights the importance of considering these factors in MS research.

* Impact of DMTs: * PwMS who were not receiving treatment had lower levels of IL-4 and β-NGF compared to healthy controls.

* Treatment with DMTs was associated with lower levels of BDNF and TNF compared to controls.

* High-efficacy DMTs were linked to reduced levels of bFGF and EGF.

* Different DMTs showed specific impacts on age-sensitive immune markers.

* Predicting Treatment Response: Lower levels of IL-6, TNF, IL-10, and β-NGF at the start of treatment were associated with subsequent clinical failure after DMT initiation.

Why This Matters: The Implications
1. Personalized Medicine: The study emphasizes the need for a personalized approach to MS treatment, considering individual factors like age, sex, and CMV status.

2. Biomarker Research: When investigating inflammation-related biomarkers in MS, it is crucial to account for age, sex, and CMV status.

3. Treatment Strategies: The findings suggest that PwMS with an immune profile similar to healthy controls before treatment might have a better prognosis on DMTs.

4. Understanding DMT Effects: Different DMTs can have distinct impacts on age-sensitive immune markers, which could influence treatment decisions.

5. Vascular Comorbidities: Vascular comorbidities in older PwMS are associated with an inflammaging profile similar to the general population.

Digging Deeper
The researchers used a variety of methods to reach these conclusions:

* Multiplex Immunoassays: Used to analyze serum samples for various immune markers.

* Unsupervised and Multivariable Analyses: Employed to identify patterns and associations in the data.

* Statistical Methods: Paired or unpaired t-tests, Mann-Whitney U tests, ANOVA or Kruskal-Wallis tests were performed according to distribution. Linear regression analyses were used to assess the relationships between age and biomarker levels.

* Longitudinal Analysis: Generalized estimating equations (GEE) were used to correct for the clustering of samples within individuals when analyzing longitudinal samples.

* Principal Component Analysis (PCA): Used to assess whether different DMTs are associated with a distinct profile of age-sensitive immune markers.

Caveats
* The study was conducted at a single center in Canada, which might limit the generalizability of the findings.

* Information on vascular comorbidities was collected retrospectively.

* The study mainly included samples collected before the widespread use of anti-CD20 therapies.

The Bottom Line
This study highlights the complex interplay between aging, sex, CMV status, and MS treatments. By considering these factors, we can move towards a more personalized approach to MS management, ultimately improving the lives of those affected by this challenging condition.

Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.

Reference:
Desu, H., Balthazard, R., Daigneault, A., Da Cal, S., Klément, W., Yu, J., ... & Larochelle, C. (2025). Peripheral blood age-sensitive immune markers in multiple sclerosis: relation to sex, cytomegalovirus status, and treatment. EBioMedicine, 112.